OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics
PUBLICATION: Breast Cancer Res Treat (2016) 156: 279. https://doi.org/10.1007/s10549-016-3764-5 AUTHORS: Inès Beumer, Anke Witteveen, Leonie Delahaye, Diederik Wehkamp, Mireille Snel, Christa Dreezen, John Zheng, Arno Floore, Guido Brink, Bob Chan, Sabine Linn, Rene Bernards, Laura van ’t Veer, Annuska Glas SUMMARY: Here we demonstrate the equivalence and reproducibility of the Read More
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli SUMMARY: Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk Read More
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients
PUBLICATION: Breast Care 2015;10:118-122 https://doi.org/10.1159/000376562. AUTHORS: Shimizu H., Horimoto Y., Arakawa A., Sonoue H., Kurata M., Kosaka T., Nakai K., Himuro T., Tokuda E., Takahashi Y., Taira F., Ito M., Abe I., Senuma K., Stork-Sloots L., de Snoo F., Saito M. SUMMARY: Of 38 cases judged to be at intermediate Read More
Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective
PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12. AUTHORS: Seguí M.Á., Crespo C., Cortés J., Lluch A., Brosa M., Becerra V., Chiavenna S.M., Gracia A. SUMMARY: A 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene Read More
MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue
PUBLICATION: J Mol Diagn. 2014 Mar;16(2):190-7. doi: 10.1016/j.jmoldx.2013.10.008. Epub 2013 Dec 28. AUTHORS: Anna Sapino, Paul Roepman, Sabine C. Linn, Mireille H.J. Snel, Leonie J.M.J. Delahaye, Jeroen van den Akker, Annuska M. Glas, Iris M. Simon, Neil Barth, Femke A. de Snoo, Laura J. van ’t Veer, Luca Molinaro, Els Read More
Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers
PUBLICATION: Breast Cancer Res Treat. 2014 Feb;144(1):103-11. doi: 10.1007/s10549-013-2830-5. Epub 2014 Jan 28.7 AUTHORS: Drukker C.A., Schmidt M.K., Rutgers E.J., Cardoso F., Kerlikowske K., Esserman L.J., van Leeuwen F.E., Pijnappel R.M., Slaets L., Bogaerts J., Van't Veer L.J. SUMMARY: Among the screen-detected cancers, 32 % had a 70-gene signature high-risk Read More
Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome
PUBLICATION: Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21. AUTHORS: Drukker C.A., van Tinteren H., Schmidt M.K., Rutgers E.J., Bernards R., van de Vijver M.J., Van't Veer L.J. SUMMARY: MammaPrint showed a significant absolute difference in DMFS and OS at 25 years between the patients with Read More
